EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension

American Heart Journal

Volumn 167, Issue 2, 2014, Pages 210-217

  Sitbon, Olivier ^a   Delcroix, Marion ^b   Bergot, Emmanuel ^c   Boonstra, Anco B ^d   Granton, John ^e   Langleben, David ^f   Subías, Pilar Escribano ^g   Galiè, Nazzareno ^h   Pfister, Thomas ⁱ   Lemarié, Jean Christophe ^j   Simonneau, Gérald ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITÉ DE CAEN   (France)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g Services of Cardiology   (Spain)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ ACTELION PHARMACEUTICALS LTD   (Switzerland)

^j Effi Stat   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARGININE; GLYCINE; MANNITOL; PROSTACYCLIN; SUCROSE; TEZOSENTAN;

6 MINUTE WALK DISTANCE; ADULT; ARTICLE; CATHETER INFECTION; CLINICAL ARTICLE; DEVICE INFECTION; DIVERTICULITIS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OPEN STUDY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; SINGLE BLIND PROCEDURE; SUPPURATION; TREATMENT SATISFACTION QUESTIONNAIRE; WALKING;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIAC CATHETERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892822456     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.08.007     Document Type: Article

References (18)

1. L.J. Rubin, J. Mendoza, and M. Hood et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial Ann Intern Med 112 1990 485 491
2. R.J. Barst, L.J. Rubin, and W.A. Long et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 302
3. N. Galiè, M.M. Hoeper, and M. Humbert et al. Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Respir J 34 2009 1219 1263
4. R.J. Barst, J.S. Gibbs, and H.A. Ghofrani et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl 2009 S78 S84
5. M.C. Chaumais, M. Jobard, and A. Huertas et al. Pharmacokinetic evaluation of continuous intravenous epoprostenol Expert Opin Drug Metab Toxicol 6 2010 1587 1598
6. Flolan® US prescribing information. http://us.gsk.com/products/ assets/us-flolan.pdf.
7. Flolan® EMA Summary of Product Characteristics. http://www.ema. europa.eu/docs/en-GB/document-library/Referrals-document/flolan-30/WC500129816. pdf.
8. O. Lambert, D. Bandilla, and R. Iyer et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted Drug Des Devel Ther 6 2012 61 70
9. O. Lambert, and D. Bandilla Stability and preservation effectiveness of a new formulation of epoprostenol sodium for the treatment of pulmonary arterial hypertension Drug Des Devel Ther 6 2012 235 244
10. L.B. Nicolas, M. Gutierrez, and J. Dingemanse Comparative pharmacokinetics, pharmacodynamics, and tolerability of three different formulations of epoprostenol sodium for injection in healthy male subjects Clin Ther 35 2013 440 449
11. M. Bharmal, K. Payne, and M.J. Atkinson et al. Validation of an abbreviated treatment satisfaction questionnaire for Medication (TSQM-9) among patients on antihypertensive medications Health Qual Life Outcomes 7 2009 36
12. M. Gomberg-Maitland, V.F. Tapson, and R.L. Benza et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension Am J Respir Crit Care Med 172 2005 1586 1589
13. O. Sitbon, A. Manes, and X. Jais et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension J Cardiovasc Pharmacol 49 2007 1 5
14. R. Barst How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? Int J Clin Pract 64 2009 23 32
15. M. Humbert, O. Sitbon, and D. Yaïci et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Eur Respir J 36 2010 549 555
16. A. Fijalkowska, M. Kurzyna, and A. Torbicki et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension Chest 129 2006 1313 1321
17. A.K. Andreassen, R. Wergeland, and S. Simonsen et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension Am J Cardiol 98 2006 525 529
18. N. Kitterman, A. Poms, and D.P. Miller et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY® Mayo Clin Proc 87 2012 825 834